Pfizer – Patient Preferences for Drug Delivery: Literature Review – RFP

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Wednesday 14th, June 2023

External Deadline: Wednesday 21st, June 2023


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: April 27, 2023

Geographic Scope: Global

Clinical Area: Patient Preferences for Drug Delivery

Link to full RFP: Patient Preferences for Drug Delivery: Literature Review

Application Due Date: June 21, 2023

Specific Area of Interest: This RFP has been developed to solicit proposals for a systematic literature review and summary of patient preference studies that include mode and frequency of treatment administration as attributes and provide quantitative estimates of the ranking or utility of different modes and frequencies of administration from the patient perspective. The specific focus of this study should be summarizing preferences for different types of non-oral/non-tablet modes of administration and the frequency with which they are used for drug administration.

The goal of this study will be to draw conclusions from the data that will allow for the generalization of these findings to indications within and across disease areas

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Derek Warnick, Grant Officer (

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: April 27, 2023